Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

pharmaceuticals sales & development sweden ab (pharmswed) - apomorphine hydrochloride hemihydrate - solution for infusion - 5 milligram(s)/millilitre - dopamine agonists; apomorphine

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - evolocumab, quantity: 420 mg - injection, solution - excipient ingredients: proline; glacial acetic acid; polysorbate 80; sodium hydroxide; water for injections - repatha is indicated as an adjunct to diet and exercise in:,prevention of cardiovascular events,repatha is indicated to reduce the risk of cardiovascular events (myocardial infarction, stroke and coronary revascularisation) in adults with established cardiovascular disease in combination with an optimally dosed statin and/or other lipid-lowering therapies (see clinical trials).,primary hypercholesterolaemia,repatha is indicated in adults with primary hypercholesterolaemia (including heterozygous familial hypercholesterolaemia and non-familial hypercholesterolaemia) to reduce low-density lipoprotein cholesterol (ldl-c): - in combination with a statin or statin with other lipid lowering therapies, or - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant.,homozygous familial hypercholesterolaemia,repatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid lowering therapies.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - evolocumab, quantity: 140 mg - injection, solution - excipient ingredients: proline; glacial acetic acid; polysorbate 80; sodium hydroxide; water for injections - repatha is indicated as an adjunct to diet and exercise in:,prevention of cardiovascular events,repatha is indicated to reduce the risk of cardiovascular events (myocardial infarction, stroke and coronary revascularisation) in adults with established cardiovascular disease in combination with an optimally dosed statin and/or other lipid-lowering therapies (see clinical trials).,primary hypercholesterolaemia,repatha is indicated in adults with primary hypercholesterolaemia (including heterozygous familial hypercholesterolaemia and non-familial hypercholesterolaemia) to reduce low-density lipoprotein cholesterol (ldl-c): - in combination with a statin or statin with other lipid lowering therapies, or - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant.,homozygous familial hypercholesterolaemia,repatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid lowering therapies.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - ondansetron hydrochloride, quantity: 4.98 mg (equivalent: ondansetron, qty 4 mg) - injection, solution - excipient ingredients: citric acid monohydrate; sodium chloride; water for injections; sodium citrate dihydrate - prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. prevention and treatment of postoperative nausea and vomiting.

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

evolan pharma ab - apomorphine hydrochloride hemihydrate - solution for infusion - 5 milligram(s)/millilitre - dopamine agonists; apomorphine

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - evolocumab, quantity: 420 mg - injection, solution - excipient ingredients: proline; glacial acetic acid; polysorbate 80; sodium hydroxide; water for injections - repatha is indicated as an adjunct to diet and exercise in:,prevention of cardiovascular events,repatha is indicated to reduce the risk of cardiovascular events (myocardial infarction, stroke and coronary revascularisation) in adults with established cardiovascular disease in combination with an optimally dosed statin and/or other lipid-lowering therapies (see clinical trials).,primary hypercholesterolaemia,repatha is indicated in adults with primary hypercholesterolaemia (including heterozygous familial hypercholesterolaemia and non-familial hypercholesterolaemia) to reduce low-density lipoprotein cholesterol (ldl-c): - in combination with a statin or statin with other lipid lowering therapies, or - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant.,homozygous familial hypercholesterolaemia,repatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid lowering therapies.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

trupharma, llc - apomorphine hydrochloride (unii: f39049y068) (apomorphine - unii:n21far7b4s) - apomorphine hydrochloride injection is indicated for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) in patients with advanced parkinson's disease. apomorphine hydrocloride inejction has been studied as an adjunct to other medications [see clinical studies (14)] . apomorphine hydrocloride is contraindicated in patients: - using concomitant drugs of the 5ht3 antagonist class including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) and alosetron [see drug interactions (7.1)] . there have been reports of profound hypotension and loss of consciousness when apomorphine hydrocloride was administered with ondansetron. - with hypersensitivity/allergic reaction to apomorphine or to any of the excipients of apomorphine hydrocloride, including a sulfite (i.e., sodium metabisulfite). angioedema or anaphylaxis may occur [see warnings and precautions (5.12)]. risk summary there are no adequate data on the developmenta

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

max health limited - apomorphine hydrochloride 5 mg/ml - solution for infusion - 5 mg/ml - active: apomorphine hydrochloride 5 mg/ml excipient: hydrochloric acid sodium chloride sodium metabisulfite water for injection - apomorphine is indicated to reduce the number and severity of 'off' phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during 'on' phases.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - palonosetron hydrochloride, quantity: 56 microgram/ml - injection, solution - excipient ingredients: mannitol; citric acid monohydrate; water for injections; sodium citrate dihydrate - palonosetron is indicated for prevention of nausea and vomiting induced by cytotoxic chemotherapy.

Βέλγιο - Αγγλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ever neuro pharma gmbh - apomorphine hydrochloride 10 mg - solution for injection in cartridge - 10 mg/ml - apomorphine hydrochloride 10 mg/ml - apomorphine